Journey Medical Corporation/ US48115J1097 /
2024-03-27 9:00:00 PM | Chg. +0.2000 | Volume | Bid11:46:25 PM | Ask11:46:25 PM | High | Low |
---|---|---|---|---|---|---|
3.8900USD | +5.42% | 122,679 Turnover: 416,536.8319 |
3.8900Bid Size: 600 | 4.0000Ask Size: 800 | 3.9800 | 3.5801 |
GlobeNewswire
03-21
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire
03-18
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the...
GlobeNewswire
03-15
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
GlobeNewswire
03-11
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the...
GlobeNewswire
01-05
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
GlobeNewswire
01-02
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
GlobeNewswire
2023-12-06
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-...
GlobeNewswire
2023-11-14
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire
2023-11-07
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highli...
GlobeNewswire
2023-10-31
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
GlobeNewswire
2023-10-20
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydroch...
GlobeNewswire
2023-09-06
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbr...
GlobeNewswire
2022-03-28
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights
GlobeNewswire
2022-03-23
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
GlobeNewswire
2022-03-18
Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update ...
GlobeNewswire
2022-03-17
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-2...
GlobeNewswire
2022-02-11
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2...
GlobeNewswire
2022-01-13
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stab...
GlobeNewswire
2021-12-10
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highli...
GlobeNewswire
2021-12-07
Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference